16 May 2021,
  • HSI:
    28,231.04 217.23 (0.78%)
    10,508.76 77.21 (0.74%)
    41,632.17 447.98 (1.09%)
    100.08 -4.05 (-3.89%)
  • HSCEI:
    10,506.00 74.45 (0.71%)
    4,076.94 -37.17 (-0.90%)
    9,425.85 16.69 (0.18%)
    16,377.71 -105.98 (-0.64%)
HSCI 10,508.8 77.2
HKSPLC25 41,632.2 448.0
HKSPGEM 100.1 -4.1
HSCEI 10,506.0 74.5
HSCCI 4,076.9 -37.2
HSFML25 9,425.9 16.7
H-FIN 16,377.7 -106.0
Stay Connected With EQS TodayIR

China Regenerative Medicine International Limited (08158.HK)

Health Care
+ More Circulars




2021 (Q1)
2020 (AR)
2020 (Q3)


China Regenerative Medicine International Limited (“CRMI”), listed on The Stock Exchange of Hong Kong Limited on 18 July 2001 (Stock Code: 8158.HK), is China’s first high-end new-technology enterprise principally engaged in research and development, production and sales of tissue engineering and regenerative medicine products. After unremitting efforts over the past decades, CRMI has evolved into a tissue engineering pioneer and has successfully industrialized regenerative medicine in the People’s Republic of China (P.R.C.), as well as accomplished the research and development and commercialization platform of tissue engineering. Headquartered in Hong Kong, CRMI has six modernized manufacturing facilities in Xi’an, Shenzhen, Suzhou, Tianjin and Hong Kong.

Currently, CRMI has applied for more than 140 domestic and overseas patents and over 170 trademarks, and has undertaken various national pivotal projects. CRMI has presided over the development of the industry standard on two occasions, and has also received many significant scientific awards including the First Class Award of the National Science and Significant Scientific Technology Award. In 2014, CRMI collaborated with the University of Oxford in the UK to establish the‘CRMI Technology Centre at the University of Oxford’ where CRMI has designated it as its core R&D institution. Following the Rolls-Royce Group and Invensys Group, CRMI is the third enterprise to set up a technology and R & D centre with the University of Oxford. On 21st October 2015, CRMI has jointly entered into the memorandum of understanding with the University of Oxford and CCB International (Holdings) Ltd, during the State Visit to the United Kingdom by President Xi Jinping of the PRC. The memorandum depicts the establishment of a strategic platform for industrialization of biomedical research which is one of the 28 projects being selected during President Xi’s visit.

CRMI currently focuses on three major business segments, namely tissue engineering, cell therapy, and cosmetics. ‘ActivSkin’, the only tissue-engineered skin developed in China that contains living cells, engraved a leading position in tissue engineering and regenerative medicine industry for us. Patients whom applied our Activeskin can shorten healing time for burns and scalds, and relieve pain. ‘Acornea’, the world’s first bio-engineered cornea which completed its clinical trials and obtained CFDA approval for commercialization, helps elevate us as well as our nation to the world stage of regenerative medicine research. The commercialization of Acornea brings hope to over 4 million patients with corneal diseases to recover vision in China. Other tissue engineering products of CRMI include: Calcined Bovine Bone – “Gegreen”, Acellular Anal Fistula Repair Stroma — “Asiunin”, Cell Sheet-Autologous Chondrocyte Implantation – “CS-ACI”, Guided Tissue Regeneration Biological Membrane–“Megreen”. With sophisticated technology and know-how on live cell culture, CRMI has launched a series of bioactive cosmetics called “Aimiya”that aims to enter the anti-aging, beauty and healthcare industry. Also, CRMI collaborated with Mila D’Opiz Group in Switzerland to establish Shanghai Hesidi Cosmetics Company Limited, which is mainly responsible for the entire business of the renowned Swiss skincare brand “Ascara” in the PRC...
+ More Company Profile

Dr. Ray Yip - Executive Director

Dr. Ray Yip (“Dr. Yip”), aged 67, is a non-executive Director. Dr. Yip joined the Group in February 2017. He is also a member of each of the Audit Committee, Nomination Committee and Remuneration Committee of the Company. He is an international public health leader who has made a significant contribution to global health in the areas of nutrition, maternal and child health, HIV/AIDS and tobacco control. Dr. Yip has been working on emergency response to war and famine, long term program and policy development effort in the PRC in recent years. Dr. Yip was the founding director of the Chinese office of U.S. Centers for Disease Control and Prevention (the “CDC”) in 2013, and the China program director of the Bill and Melinda Gates Foundation(the “Foundation”) in 2017. Dr. Yip is known as a specialist for health and medical issues in the PRC.

Dr. Yip’s major contributions to the global health include: refining the international criteria for screening for malnutrition and anemia and increasing the awareness of diarrhea as a major contributor to acute malnutrition. His work in the PRC has resulted in the mainstreaming of hepatitis B vaccine for routine immunization, the adoption of hospital- based delivery as a strategy which significantly reduced maternal mortality, transformation of the national AIDS response to one targeting those high-risk groups by accepting the role of civil society and assisting in engineering the policy support for tobacco control at the top level.

Dr. Yip established the Foundation’s mission in China by assisting the government in addressing the key public health issues such as HIV and tobacco. He also transformed the Foundation’s strategy in giving it a new focus “China-for-Africa” which includes identifying successful Chinese experience and technology to assist in the development of Africa. Since 2017, Dr. Yip has served as a special advisor focusing on health and clean energy for bgC3, a think-tank headed by Bill Gates.  

Dr. Yip served at the faculty of the University of California-San Francisco between 1990 and 1994 and was an adjunct professor at the Friedman School and Nutrition Science and Policy of Tufts University between 2006 and 2010. Currently, Dr. Yip is an adjunct professor at the Research Centre for Public Health of Tsinghua University.  

Dr. Yip graduated from the Medical School and the School of Public Health of the University of Minnesota, and he was then certified as a pediatric haematologist-oncologist.

Mr. Chan Bing Woon, SBS, JP - Independent Non-Executive Director

Mr. Chan Bing Woon, SBS, JP, (“Mr. Chan”), aged 73, is an independent non-executive Director. He is also a member of each of the Audit Committee, Nomination Committee and Remuneration Committee. Mr. Chan joined the Group in March 2014. Mr. Chan is a consultant of Yung, Yu, Yuen & Co., Solicitors and Notaries. He has over 40 years’ experience in the legal profession. Mr. Chan has been involved in numerous public duties including being Advisor of the Joint Mediation Helpline Office. He is also a fellow member of the Hong Kong Institute of Directors, a council member of the Hong Kong Society of Notaries, a general accredited mediator of Hong Kong International Arbitration Centre and the Law of Society of Hong Kong, and the chairman of the Hospital Governing Committee of Castle Peak Hospital and Siu Lam Hospital. Mr. Chan was a member of the Hospital Authority and a past chairman of the Hong Kong Mediation Council. He is currently an independent non-executive director of Kwoon Chung Bus Holdings Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 306).

Mr. Wong Yiu Kit Ernest - Independent Non-Executive Director

Mr. Wong Yiu Kit Ernest (“Mr. E Wong”), aged 49, is an independent non-executive Director. He is also the member of each of the Audit Committee, Nomination Committee and Remuneration Committee. Mr. E Wong joined the Group in February 2017. He has over 25 years of experience in venture capital, corporate finance, business development and general management. Mr. E Wong has served as the president and group chief financial officer of KVB Kunlun Holdings Limited (“KVB”) since November 2011 and as the chief financial officer and the company secretary of KVB’s group company, KVB Kunlun Financial Group Limited (the shares of which are listed on the Stock Exchange, HKEx stock code: 8077) since October 2014. Mr. E Wong has also served as an independent non-executive director of Renheng Enterprise Holdings Limited (HKEx stock code: 3628) since October 2011, HongDa Financial Holding Limited (HKEx stock code: 1822) since July 2014, Legend Strategy International Holdings Group Company Limited (HKEx stock code:1355) since November 2016 and Progressive Path Group Holdings Limited (HKEx stock code: 1581) since November 2016.

Mr. E Wong also served several positions at Adamas Finance Asia Limited (LSE stock code: ADAM), including its executive director from May 2008 to February 2014, its chief financial officer from May 2008 to October 2011 and its non-executive director since February 2014.

Mr. E Wong obtained a bachelor’s degree in business administration from The University of Hong Kong in 1991, a master’s degree of science in investment management from The Hong Kong University of Science and Technology in 1998 and a master’s degree of science in electronic engineering from The Chinese University of Hong Kong in 2008.

Mr. E Wong was admitted as a fellow member of the Association of Chartered Certified Accountants and the Hong Kong Institute of Certified Public Accountants in November 1999 and October 2002, respectively. He was admitted as a chartered financial analyst of the Institute of Chartered Financial Analysts in September 1998 and an associate member of the Institute of Chartered Accountants in England and Wales in January 2008. He is also acting as the president of the Hong Kong University Graduates Association, the deputy chairman of the HKU Convocation, the court member of The University of Hong Kong, a committee member of the Association of Chartered Certified Accountants Hong Kong and an executive director of the Hong Kong Society of Financial Analysts.

+ More Board of Directors


2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31          




Listed Date 18 Jul 2001

Address 10th Floor, Everbright Centre, 108 Gloucester Road, Wanchai, Hong Kong

Telephone (852) 3966-8388

Facsimile (852) 2802-0026

Email info@crmi.hk

No. of Click Rate